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Abstract 
High doses of ionizing radiation induce acute damage to epithelial cells of the gastrointestinal (GI) 
tract, mediating toxicities restricting the therapeutic efficacy of radiation in cancer and morbidity 
and mortality in nuclear disasters. No approved prophylaxis or therapy exists for these toxicities, 
in part reflecting an incomplete understanding of mechanisms contributing to the acute 
radiation-induced GI syndrome (RIGS). Guanylate cyclase C (GUCY2C) and its hormones guanylin 
and uroguanylin have recently emerged as one paracrine axis defending intestinal mucosal 
integrity against mutational, chemical, and inflammatory injury. Here, we reveal a role for the 
GUCY2C paracrine axis in compensatory mechanisms opposing RIGS. Eliminating GUCY2C 
signaling exacerbated RIGS, amplifying radiation-induced mortality, weight loss, mucosal 
bleeding, debilitation and intestinal dysfunction. Durable expression of GUCY2C, guanylin and 
uroguanylin mRNA and protein by intestinal epithelial cells was preserved following lethal 
irradiation inducing RIGS. Oral delivery of the heat-stable enterotoxin (ST), an exogenous GUCY2C 
ligand, opposed RIGS, a process requiring p53 activation mediated by dissociation from MDM2. 
In turn, p53 activation prevented cell death by selectively limiting mitotic catastrophe, but not 
apoptosis. These studies reveal a role for the GUCY2C paracrine hormone axis as a novel 
compensatory mechanism opposing RIGS, and they highlight the potential of oral GUCY2C 
agonists (Linzess™; Trulance™) to prevent and treat RIGS in cancer therapy and nuclear disasters. 
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Introduction 
Exposure to radiation in the context of terrorist attacks or natural disasters produces death 
within about 10 days reflecting toxicity to the gastrointestinal (GI) tract, constituting the acute 
radiation-induced GI syndrome (RIGS) (1-3). In contrast to radiation-induced bone marrow 
toxicity, in which death can be prevented by bone marrow transplantation, there are no 
approved management paradigms to prevent or treat RIGS (4). Importantly, radiation therapy 
remains a mainstay in the management of cancer, a leading cause of death worldwide. Radiation 
therapy destroys rapidly proliferating cancer cells and, inevitably, normal tissues characterized 
by continuous regeneration programs, including hair follicles, bone marrow, the GI tract as well 
as other glandular epithelia (5). In that context, dose-limiting toxicities of radiation discourage 
patients from completing therapy; restrict maximum doses of radiation which limits the efficacy 
of treatment; and can lead to chronic morbidity and mortality (5). 
Inadequate management in part reflects an incomplete understanding of mechanisms underlying 
RIGS. Indeed, critical molecular mechanisms and cellular targets mediating epithelial toxicity 
underlying RIGS remain controversial (6-14). Recent studies suggest that p53 in intestinal 
epithelial cells principally controls radiation-induced GI toxicity in mice, independently of 
apoptosis (7). In that context, deletion of the intrinsic apoptotic pathway from intestinal 
endothelial or epithelial cells failed to protect mice from GI toxicity-related death (7). In contrast, 
tissue-specific targeted deletion of intestinal epithelial cell p53 exacerbates, while its over-
expression rescues, RIGS in mice (7,14). However, mechanisms underlying radiation-induced 
intestinal epithelial cell death and intestinal mucosa damage remain undefined (7). 
GUCY2C is the intestinal receptor for the endogenous paracrine hormones guanylin (GUCA2A) 
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and uroguanylin (GUCA2B) and the heat-stable enterotoxins (STs) produced by diarrheagenic 
bacteria (15-17). This signaling axis plays a central role in mucosal physiology, regulating fluid and 
electrolyte secretion (15,16), and in coordinating crypt-surface homeostasis, regulating 
enterocyte proliferation, differentiation, metabolism, apoptosis, DNA repair, and epithelial-
mesenchymal cross-talk (18-20). Further, this axis maintains the intestinal barrier, opposing 
epithelial injury induced by carcinogens, inflammation, and radiation, and its dysfunction 
contributes to the pathophysiology of inflammatory bowel disease and tumorigenesis (19-30). 
While the GUCY2C signaling axis has emerged as one guardian of intestinal epithelial integrity, 
the role of this axis in responses to lethal radiation, and its utility as a therapeutic target to 
prevent and treat RIGS remains undefined (22). 
Here, we define a novel role for the GUCY2C paracrine hormone axis in compensatory responses 
opposing RIGS. Indeed, eliminating GUCY2C signaling amplifies radiation-induced GI toxicity. In 
that context, durable expression of GUCY2C, GUCA2A, and GUCA2B mRNA and protein is 
preserved following high doses of radiation that induce RIGS. Moreover, oral administration of 
the GUYC2C ligand ST opposed RIGS through a p53-dependent mechanism associated with the 
rescue of intestinal epithelial cells selectively from mitotic catastrophe, but not from apoptosis. 
These observations reveal a previously unrecognized compensatory mechanism to epithelial 
injury induced by high-dose radiation, involving signaling by the GUCY2C paracrine axis that 
opposes RIGS. They highlight the potential for oral GUCY2C-targeted agents to prevent or treat 
RIGS in the setting of cancer radiotherapy or environmental exposure through nuclear accident 
or terrorism. The opportunity to immediately translate these approaches is underscored by the 
recent regulatory approval of linaclotide (Linzess™) and plecanatide (Trulance™), oral GUCY2C 
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ligands that treat chronic constipation (31). 
Materials and Methods 
Animal models 
Mice with a targeted germline deletion of GUCY2C (Gucy2c-/-) are well-characterized, and were 
used after >14 generations of backcrossing onto the C57BL/6 background (15,16,18-20,26,32). 
p53FL-vil-Cre-ERT2 mice were generated by crossbreeding vil-Cre-ERT2 (provided by S. Robine, 
Institut Curie-CNRS, France) with p53FL transgenic mice (mixed FVB.129 and C57BL/6 
backgrounds, kindly provided by Dr. Karen Knudsen, Thomas Jefferson University, Philadelphia, 
PA). Biallelic loss of p53 in intestinal epithelial cells (p53int-/-) was induced by IP administration of 
tamoxifen (75 mg tamoxifen/kg/d x 5 d) to F2 p53FL-vil-Cre-ERT2 and control littermate p53+-vil-
Cre-ERT2, and deletion confirmed structurally by immunoblot analysis of phosphorylated p53 
(pp53; Supplementary Fig. 1) and functionally by radiation-induced mortality (Supplementary Fig. 
2). All experiments were carried out with mice that were between 2 to 3.5 months old (mixed 
males and females) and all mice were on mixed genetic backgrounds as described above and in 
Supplementary Figure 3. Where appropriate, age-matched and littermate controls were utilized 
to minimize the effect of genetic backgrounds. C57BL/6 mice used in oral ST or control peptide 
supplementation studies were obtained from NIH (NCI-Frederick) while those used for GUCY2C 
and ligand expression analysis were obtained from the Jackson Laboratory (Bar Harbor, ME). This 
study was approved by the Institutional Animal Care and Use Committee of Thomas Jefferson 
University (protocol 01518). 
Gamma irradiation-induced GI toxicity 
Anesthetized mice were irradiated with total-body gamma irradiation (TBI) or with back limbs to 
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tail and front limbs to head shielded with lead covers for subtotal-body irradiation (STBI) with 
exposure of abdominal area (approximately 1 inch2 from xiphoid to pubic symphysis). Mice were 
irradiated with a 137Cs irradiator (Gammacell 40) at a dose rate of approximately 70 cGy/min for 
different doses from 8 to 25 Gy/mice. Mice had free access to regular food and water before and 
after irradiation. The severity of GI toxicity was evaluated by mortality, debilitation (untidy fur 
coats), body weight, visible diarrhea, fecal occult blood, stool formation, stool water 
accumulation, and histopathology. 
ST and control peptides 
ST1-18 and control peptide (CP; inactive ST analog contains the same primary amino acid 
sequence, but with cysteines at positions 5, 6, 9, 10, 14, 17 replaced by alanine) were purchased 
from Bachem Co. (customer order; purity > 99.0%). ST and control peptides were resuspended in 
1 X phosphate-buffered saline (PBS) at a concentration of 50 ng/μL. Mice were orally gavaged 
with 10 μg of CP or ST (in 200 μL solution) using a feeding needle (cat. # 01-208-88, Fisher 
Scientific) (26) daily for 14 d before and 14 d after irradiation. ST and CP were prepared by solid 
phase synthesis and purified by reverse phase HPLC, their structure confirmed by mass 
spectrometry by Bachem Co. (customer order; purity > 99.0%), and their activities confirmed by 
quantifying competitive ligand binding, guanylate cyclase activation and secretion in the suckling 
mouse assay (16,33). 
Reagents 
McCoy's 5A and Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal bovine serum 
and other reagents for cell culture were obtained from Life Technologies (Rockville, MD). 8-
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Bromoguanosine 3’, 5’-cyclic monophosphate (8-Br-cGMP), a cell-permeant analog of cGMP, was 
obtained from Sigma (St. Louis, MO) and 500 µM was used in all experiments (18,20,25,26,34). 
Cell lines 
C57BL/6-derived EL4 lymphoma cells (lymphoblasts in mouse thymus; thymoma), C57BL/6-
derived B16 melanoma cells, and HCT116 (wild-type p53) human colon cancer cells, which lack 
GUCY2C (Supplementary Fig. 4) (19,34,35), were obtained from ATCC (Manassas, VA). Isogenic 
HCT116-p53-null cells were a gift from Dr. Bert Vogelstein (Johns Hopkins University, MD) (36). 
Cell lines were authenticated employing established transcriptomic, proteomic, phenotypic and 
functional characteristics. Cell stocks were refreshed after the earlier of 10 passages or two years, 
and were screened for mycoplasma contamination every 6 months with the Universal 
Mycoplasma Detection Kit (ATCC). Cell lines were obtained and used in 2010-2011. 
Ectopic tumor seeding and growth measurement 
EL4 and B16 cells (104 cells per injection) were injected subcutaneously in mouse flanks (EL4, left 
and B16, right). Tumor growth was measured once every 3 d and tumor volume was calculated 
by multiplying 3 tumor dimensions. No significant differences in tumor growth before and after 
subtotal body irradiation was observed in mice treated with ST compared to CP. 
Immunoblot analyses 
Protein was extracted from mouse small intestine and colon mucosa in T-Per reagent (Pierce, 
Dallas, TX), or from in vitro cell lysates in Laemmli buffer, and supplemented with protease and 
phosphatase inhibitors (Roche, Indianapolis, IN). Protein was quantified by immunoblot analysis 
employing antibodies to: phosphorylated histone H2AX (cat. # 2577, 1:200 dilution), 
phosphorylated p53 (cat. # 9284, 1:200 dilution), cleaved caspase 3 (cat. # 9579, 1:200 dilution), 
9 
 
Mdm2 (cat. # 3521, 1:200 dilution), and GAPDH (cat. # 2118, 1:200 dilution) from Cell Signaling 
Technology (Danvers, MA), phosphorylated histone H2AX (cat. #05-636, 1:1000 dilution) from 
Millipore (Billerica, MA), and p53 (cat. # sc-126, 1:1000 dilution) from Santa Cruz (Santa Cruz, CA). 
The antibody to GUCY2C was validated previously (25,26). Antisera to GUCA2A and GUCA2B were 
generously provided by Dr. Michael Goy (University of North Carolina, Chapel Hill, NC) (37,38). 
Secondary antibodies conjugated to horseradish peroxidase were from Jackson Immunoresearch 
Laboratories (West Grove, PA). Staining intensity of specific bands quantified by densitometry 
was normalized to that for GAPDH using a Kodak imaging system. Average relative intensity 
reflects the mean of at least three animals in each group and the mean of at least two 
independent experiments. Molecular weight markers (Cat. # 10748010, 5 µL per run, or Cat. 
#LC5800, 10 µL per run) for immunoblot analyses were from Invitrogen (Grand Island, NY). 
Secondary antibodies specific to light chains, including goat anti-mouse IgG (cat. # 115-065-174) 
and mouse anti-rabbit IgG (cat. # 211-062-171), were from Jackson Immunoresearch 
Laboratories (Suffolk, UK) for immunoblot analysis following immunoprecipitation. 
Immunoprecipitation 
Protein from 8-10 x 106 HCT116 cells was extracted in 1% NP40 immunoprecipitation (IP) lysis 
buffer supplemented with protease and phosphatase inhibitors and incubated with antibodies 
to Mdm2 (cat. # 3521, 5 µg) from Cell Signaling Technology and p53 (cat. # sc-126, 1 µg) from 
Santa Cruz and protein A beads (Invitrogen, Grand Island, NY) overnight followed by six washes. 
Precipitated proteins were collected in Laemmli buffer (with 5% beta mercaptoethanol) 
supplemented with protease and phosphatase inhibitors (Roche) and quantified by immunoblot 
analysis employing antibodies to Mdm2 (cat. # 3521, 1:200 dilution) from Cell Signaling 
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Technology and p53 (cat. # sc-126, 1:1000 dilution) from Santa Cruz. Mouse IgG (5 µg, cat. # 
10400C, Invitrogen) and rabbit IgG (5 µg, cat. # 10400C, Invitrogen) were isotype controls for 
immunoprecipitation. 
Immunohistochemistry and immunofluorescence 
Antigens were unmasked in paraffin-embedded sections (5 μm) by heating at 100o C for 10 min 
in 10 mM citric buffer, ph 6.0. In addition to those already described, antibodies to antigens 
probed here included: phosphorylated histone H2AX from Cell Signaling (cat. # 2577, 1:200 
dilution), or from Millipore (cat. #05-636, 1:1000 dilution), cleaved caspase 3 from Cell Signaling 
(cat. # 9579, 1:200 dilution), and β-catenin from Santa Cruz (cat. # sc-7199, 1:50 dilution). The 
antibody to GUCY2C (25,26) and the antisera to GUCA2A and GUCA2B were described previously 
(37,38). Fluorescent secondary antibodies were from Invitrogen. Tyramide signal amplification 
was used to detect GUCY2C and GUCA2A; secondary antibodies conjugated to horseradish 
peroxidase were from Jackson Immunoresearch Laboratories (cat #115-035-206 and #111-036-
046, 1:1000 dilution), and fluorescein-conjugated tyramine was prepared from tyramine HCl (cat 
#T2879, Sigma) and NHS-fluorescein (cat #46410, Thermo Scientific) (39). Phosphorylated 
histone H2AX-positive cells were quantified in 200-1000 crypts per section per animal and 
positive cells normalized to crypt number. Results reflect the means ± SEM of at least 3 animals 
in each group. Immunofluorescence stains were performed in HCT116 and HCT116 p53-null cells 
using antibodies to the following antigens included: α/β-tubulin from Cell Signaling (cat. # 2148, 
1:200 dilution) and γ-tubulin from Abcam (cat. #ab11317, 1:100 dilution, Cambridge, MA). 
Fluorescence images were captured with an EVOS FL auto cell imaging system from Life 
Technologies-Thermo Fischer Scientific (Waltham, MA). 
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Cell treatment, irradiation and colony formation assay 
HCT116 and HCT116 p53-null cells were plated in 6-well dishes at 1 x 104 cells/well followed by 
treatment for 7 d with vehicle or cell permeable cGMP (8-Br-cGMP, 500 µM). Media containing 
different treatments were changed every other day. After exposure to radiation (0-4 Gy) cells 
were trypsinized and plated in 6-well dishes at different densities depending on the potency of 
the treatments (104 cells/well for HCT116 exposed at 0, 1 and 2 Gy; 4 x 104 cells/well for HCT116 
p53-null exposed at 0, 1 and 2 Gy; 50 x 104 cells/well for HCT116 exposed at 3 and 4 Gy; 200 x 
104 cells/well for HCT116 p53-null exposed at 3 and 4 Gy). Cells were treated with vehicle or 8-
Br-cGMP for 7 d after irradiation, then fixed and stained with 10% methylene blue in 70% ethanol. 
The number of colonies, defined as >50 cells/colony were counted, and the surviving fraction was 
calculated as the ratio of the number of colonies in the treated sample to the number of colonies 
produced by cells that were not irradiated. Triplicates were used for each condition in three 
independent experiments. 
Anaphase bridge index (ABI) and aneuploidy 
Cells preconditioned with 8-Br-cGMP, or control cells, were irradiated (5 Gy), then seeded on 
coverslips in 24-well plates (5 X 104 cells per well). ABI and aneuploidy were quantified 2 d after 
irradiation. 
ABI: Cells were fixed in 4% PFA and stained with DAPI. Anaphase cells were analyzed and 
abnormal anaphase cells were calculated under a fluorescence microscope. More than 200 
anaphase cells were analyzed in each treatment group in each independent experiment. Any 
abnormal anaphase cells with anaphase bridges or anaphase lag showing extended chromosome 
bridging between two spindle poles were enumerated and the ABI was calculated as percentage 
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of abnormal anaphase cells over total anaphase cells. 
Aneuploidy: Cells were fixed in 4% PFA and stained with DAPI, and immunofluorescence stains 
were performed using α/β-tubulin-specific antibodies and centromere-specific γ-tubulin 
antibodies, detected with Alexa Fluor® 555 or Alexa Fluor® 488 labeled secondary antibodies 
from Invitrogen. Images were acquired with a laser confocal microscope (Zeiss 510M and Nikon 
C1 Plus, Thomas Jefferson University Bioimaging Shared Resource), and 0.5 μm optical sections 
in the z axis were collected with a 100 × 1.3 NA oil immersion objective at room temperature. 
Iterative restoration was performed using LSM Image Brower (Zeiss), and images represent three 
to four merged planes in the z axis. Abnormal anaphase chromatids were counted if cells 
contained more than two centrosomes or two centrosomes located in the same direction to the 
spindle midzone separated from kinetochores at the poles. 
Quantitative RT-PCR analysis 
Transcripts for GUCY2C, GUCA2A, and GUCA2B were quantified by RT-PCR employing primers 
and conditions described previously (25,26). 
125I-labeled ST binding 
Binding of 125I-labeled ST to GUCY2C was performed as described previously (33). Briefly, 
membranes were prepared from cells as described previously (33) and ST was iodinated (125I-
Tyr4-ST) to a final specific activity of 2,000 Ci/mmol (33). Total binding was measured by counts 
per minute (CPM) in the absence of unlabeled ST competition, whereas nonspecific binding was 
measured in the presence of 1 x 10-5 M unlabeled ST. Specific binding was calculated by 
subtracting nonspecific binding from total binding (33). Assays were performed at least in 
triplicate. 
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Statistical analyses 
Statistical significance was determined by unpaired two-tailed Student's t test unless otherwise 
indicated. Results represent means ± SEM from at least 3 animals or 3 experiments performed in 
triplicate. Survival and disease-free survival were analyzed by Kaplan-Meier analysis. Body weight 
was analyzed using a frailty model combining a segmented linear longitudinal model of body 
weight, a log-normal model for survival time, and a log-normal model for random break point for 
body weight (inflection point). Analyses of fecal occult blood and untidy fur were performed by 
Cochran-Mantel-Hansel test. Colony formation was analyzed by a pairwise comparison in four 
treatments with isotherm slopes by linear regression. 
Results 
Silencing GUCY2C exacerbates RIGS. A role for GUCY2C in opposing epithelial cell apoptosis 
induced by low doses of ionizing radiation (22) suggested that this receptor may play a role in 
RIGS. Targeted germline deletion of Gucy2c (Gucy2c-/- mice) (15,16,18-20,26,32) accelerated the 
death of mice following exposure to a lethal dose (high dose, 15 Gy) of total body irradiation (TBI; 
Fig. 1A). This dose of radiation produced death by inducing RIGS which could not be rescued by 
bone marrow transplantation, in contrast to low dose (8 Gy) radiation which produced the 
hematopoietic, but not the GI, syndrome (Fig. 1B). Similarly, silencing GUCY2C signaling 
exacerbated acute GI toxicity quantified by diarrhea (Fig. 1C) and decreased survival (Fig. 1D) 
following 18 Gy sub-total abdominal irradiation (STBI), with bone marrow preservation by 
shielding. Exacerbation of RIGS in the absence of GUCY2C signaling was associated with increased 
intestinal dysfunction, including weight loss (Fig. 1E), intestinal bleeding (Fig. 1F), debilitation 
(untidy fur, Fig. 1G) (40), and stool water accumulation (Fig. 1H) (41). Silencing GUCY2C signaling 
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amplified intestinal epithelial disruption, quantified as crypt loss, produced by STBI in small 
intestine (Fig. 1I-J). Moreover, it created novel epithelial vulnerability in the colon, which is 
relatively resistant to RIGS (Fig. 1K-L) (1-5). Together, these observations reveal that the GUCY2C 
signaling axis plays a compensatory role in modulating mechanisms contributing to RIGS. 
GI-toxic irradiation preserves durable expression of GUCY2C and its paracrine hormones. A role 
for the GUCY2C paracrine hormone axis in compensatory mechanisms opposing RIGS is 
predicated on the persistence of expression of the receptor and its hormones following high 
doses of radiation. Indeed, GUCY2C mRNA and protein, characteristically expressed along the 
entire crypt-villus axis (17), was durably preserved following lethal TBI (Fig. 2A, B, C), a result that 
is similar to other conditions disrupting epithelial integrity, including tumorigenesis (18-20,25). 
Unexpectedly, GI-toxic TBI preserved expression of GUCA2A (Fig. 2D, E, F) and GUCA2B (Fig. 2G, 
H, I), in contrast to other modes of disrupting epithelial integrity, including tumorigenesis, 
inflammatory bowel disease, and metabolic stress in which ligand expression is lost (18-21,25,26). 
Indeed, expression of GUCA2A, which is low in small intestine, was retained primarily in isolated 
epithelial cells, as described previously (42). In contrast, expression of GUCA2B, which is the 
predominant GUCY2C hormone in the small intestine, was retained principally by differentiated 
epithelial cells in distal villi (42). Preservation of receptor and hormone expression was durable, 
and there were no significant differences in mRNA or protein levels across the time course of 
injury response (Fig. 2; Supplementary Fig. 5). Moreover, preservation of hormone expression 
was independent of GUCY2C expression (Supplementary Fig. 6). These observations are 
consistent with a role for the GUCY2C paracrine hormone signaling axis in compensatory 
responses that oppose acute radiation-induced GI toxicity. Moreover, the persistence of receptor 
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expression across the continuum of injury response suggests the potential utility of GUCY2C as a 
therapeutic target to prevent RIGS. 
GUCY2C activation by oral ligand rescues RIGS, but not extra-GI tumor responses to radiation. 
In wild type mice, oral administration of ST, an exogenous GUCY2C ligand, reduced morbidity and 
mortality induced by STBI, quantified by the incidence of diarrhea (Fig. 3A) and survival (Fig. 3B) 
respectively. Similarly, oral ST opposed STBI-induced intestinal dysfunction, including weight loss 
(Fig. 3C), intestinal bleeding (Fig. 3D), debilitation (Fig. 3E), and stool water accumulation (Fig. 3F). 
Further, oral ST rescued intestinal morphology and stool formation (Fig. 3G), and water 
reabsorption associated with preservation of normal histology (Fig. 3H) after STBI. In contrast, 
oral ST did not rescue RIGS in Gucy2c-/- mice (Supplementary Fig. 7). Furthermore, oral ST did not 
alter therapeutic radiation responses of radiation-sensitive thymoma or radiation-resistant 
melanoma (Fig. 3I). Moreover, chronic oral ST was safe, without adverse pharmacological effects 
like diarrhea (Fig. 3J) or growth retardation (Fig. 3K). These observations support the suggestion 
that GUCY2C signaling comprises a compensatory mechanism opposing RIGS that can be engaged 
by orally administered ligands. Indeed, GUCY2C ligands safely protect intestinal epithelial cells 
specifically (26), without altering therapeutic responses to radiation of tumors outside the 
intestine.  
GUCY2C signaling opposing RIGS requires p53. GUCY2C signaling protects intestinal epithelial 
cells from apoptosis induced by low dose radiation (22). However, while silencing GUCY2C 
signaling increased basal levels of apoptosis in small intestine, as demonstrated previously (18), 
it did not alter apoptosis associated with RIGS along the rostral-caudal axis of the intestine across 
the continuum of injury responses (Fig. 4A). In that context, p53 also opposes RIGS through 
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mechanisms that are independent of apoptosis (Supplementary Fig. 8) (7). Indeed, eliminating 
p53 phenocopied GUCY2C silencing, exacerbating RIGS-related mortality (Fig. 1D; Supplementary 
Fig. 2). Further, activation of GUCY2C with oral ST improved survival in wild type, but not  
p53int-/-, mice following STBI (Fig. 4B). Moreover, GUCY2C activation opposed STBI-induced 
intestinal dysfunction quantified by body weight loss (Fig. 4C), intestinal bleeding (Fig. 4D) and 
debilitation (Fig. 4E) in wild type, but not in p53int-/-, mice. These observations suggest that the 
GUCY2C signaling axis opposes RIGS through a mechanism requiring p53. 
GUCY2C signaling opposing RIGS is associated with amplification of p53 responses. Consistent 
with a role for p53 in mediating the effects of GUCY2C signaling on radiation-induced intestinal 
toxicity, oral ST increased levels of phosphorylated p53 in mouse intestinal epithelial cells in RIGS 
induced by STBI (Fig. 4F). Recapitulating these in vivo results, the GUCY2C second messenger, 
cGMP, increased total and phosphorylated p53 induced by radiation in HCT116 human colon 
carcinoma cells (Fig. 4G), an in vitro model of intestinal epithelial cells that express wild type p53, 
but not GUCY2C (19,34,35) (Supplementary Fig. 4). Amplification of p53 responses to radiation 
induced by cGMP signaling in HCT116 cells was associated with reduced interactions between 
p53 and the inhibitory protein Mdm2 (Fig. 4H). 
GUCY2C signaling opposing RIGS is associated with p53-dependent rescue of mitotic 
catastrophe. Induction of GUCY2C signaling by oral ST opposed chromosomal instability in 
intestinal epithelial cells following STBI, reducing double-strand DNA breaks (Fig. 5A) and 
abnormal mitoses characteristically associated with mitotic catastrophe (Fig. 5B). Similarly, 
chromosomal instability produced by irradiation, quantified by centrosome counts or the 
anaphase bridge index (43), was reduced in HCT116 cells treated with 8-Br-cGMP (Fig. 5C-D). In 
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contrast, elimination of p53 (HCT116 p53-/-) amplified chromosomal instability produced by 
irradiation, and this damage was insensitive to 8-Br-cGMP (Fig. 5C-D). Moreover, cell death by 
mitotic catastrophe reflecting radiation-induced aberrant mitosis was reduced by cGMP in 
parental, but not in p53-/-, HCT116 cells (Fig. 5E). 
DISCUSSION 
RIGS reflects radiation-induced genotoxic stress in intestinal epithelial cells (7-9,11,12,14). 
Radiation produces DNA damage, directly and through reactive oxygen species (23), activating 
p53 (7,9,14,44). In turn, p53 mediates a bifurcated injury response. Cells damaged beyond repair 
undergo caspase-dependent apoptosis initiated by p53 activation of PUMA (6,9,12,13). Further, 
in cells that can be rescued, p53 induces the expression of p21, a key inhibitor of cyclin-
dependent kinases which regulates cell cycle checkpoints (7,9,14). Inhibition of proliferation 
associated with these checkpoints permits cells to repair damaged DNA (7-9,12,14,45). However, 
p53 responses are limited and cells with damaged DNA escape checkpoints within days of 
irradiation, enter prematurely into the cell cycle with damaged DNA, and undergo mitotic 
catastrophe (7,9,12,14,46). In turn, this produces epithelial loss and mucositis, disrupting barrier 
function associated with fluid and electrolyte loss and infection which are principle mechanisms 
of death from RIGS (47). Here, we reveal an unexpected compensatory mechanism that opposes 
this pathophysiology, involving the GUCY2C signaling axis at the intersection of radiation injury 
and p53 responses. 
GUCY2C is selectively expressed by intestinal epithelial cells and activation by the endogenous 
hormones guanylin and uroguanylin, or the diarrheagenic bacterial STs, increases intracellular 
cGMP accumulation (17). While there is evidence for GUCY2C signaling in other tissues (32,48), 
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the effect of oral ST in ameliorating RIGS in the present study is consistent with a primary effect 
on intestinal receptors, reflecting the absence of bioavailability of oral GUCY2C ligands (31). 
GUCY2C-cGMP signaling modulates intestinal secretion, one mechanism by which bacteria 
induce diarrhea, and the oral GUCY2C ligands linaclotide (Linzess™) and plecanatide (Trulance™) 
improve constipation and relieve abdominal pain in patients with irritable bowel syndrome 
(31,49). Further, GUCY2C signaling regulates proliferation and DNA damage repair, processes 
that are canonically disrupted in RIGS (26). Indeed, signaling through the GUCY2C-cGMP axis 
inhibits DNA synthesis and prolongs the cell cycle, imposing a G1-S delay in part by regulating 
p21, key injury responses to radiation (18-20,50). Further, silencing GUCY2C increases DNA 
oxidation and double strand breaks, amplifying mutations induced by chemical or genetic DNA 
damage, reflecting ROS and inadequate repair (20). Moreover, silencing GUCY2C disrupts the 
intestinal barrier (26), a key pathophysiological mechanism contributing to RIGS (47). Conversely, 
GUCY2C ligands block that damage, enhancing barrier integrity and accelerating recovery from 
injury (23,24,26,27,30). This role in promoting mucosal barrier integrity supports GUCY2C as a 
therapeutic target for RIGS. 
The present observations suggest a previously unrecognized compensatory mechanism opposing 
RIGS in which the paracrine hormones guanylin and uroguanylin activate GUCY2C-cGMP signaling 
to defend the integrity of the intestinal epithelial barrier. In that model, paracrine hormone 
stimulation of the GUCY2C-cGMP signaling axis supports p53 responses to radiation injury by 
disrupting interactions with Mdm2, a key regulator of responses to genotoxic stress which binds 
to the amino terminal of 18-19.p53, inhibiting its transactivation function and targeting it for 
proteasomal degradation (45,51,52). In turn, amplified p53 responses contribute to resolving 
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DNA damage, limiting mitotic catastrophe (7). Beyond these compensatory responses, the 
durable preservation of GUCY2C expression following high dose irradiation across the rostral-
caudal axis of the intestine and the continuum of injury responses offers an opportunity to target 
this receptor for mitigation of RIGS by oral GUCY2C hormone administration. Indeed, it creates 
the unique possibility of transforming RIGS from a syndrome of irreversible DNA damage to one 
that can be reversed or prevented by oral GUCY2C ligand supplementation. 
These studies stand in contradistinction to other models of intestinal injury in which homeostasis 
is disrupted through paracrine hormone loss silencing GUCY2C. Indeed, guanylin and uroguanylin 
are the most commonly lost gene products in sporadic colorectal cancer and these hormones are 
lost at the earliest stages of neoplasia (29,53,54). Hormone loss silences the GUCY2C signaling 
axis and interrupts canonical homeostatic mechanisms that regulate the continuously 
regenerating intestinal epithelium and whose disruption is essential for tumorigenesis (17-
20,25,26,34). Similarly, while obesity and colorectal cancer are associated, underlying 
mechanisms have remained unclear. Recent studies revealed that over-consumption of calories, 
which is an essential mechanism contributing to obesity, produces ER stress leading to guanylin 
loss silencing the GUCY2C tumor suppressor (25). Indeed, replacing guanylin suppressed by 
calories eliminated tumorigenesis (25). Moreover, oral dextran sulfate injures intestinal mucosa, 
producing inflammatory bowel disease (IBD), and silencing GUCY2C amplifies injury in IBD, 
increasing mortality in mice (24,26,30). Indeed, IBD is associated with GUCY2C paracrine 
hormone loss in humans (21). In the context of this emerging paradigm of intestinal epithelial 
injury, the present results demonstrating the preservation of paracrine hormone expression in 
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the context of high dose irradiation was unexpected. However, they are consistent with a role 
for the GUCY2C paracrine hormone axis in compensatory mechanisms opposing RIGS. 
Previous studies revealed that silencing GUCY2C amplified apoptosis induced by low doses of 
radiation (5 Gy) (22). These radiation doses are below GI-toxic levels which produce RIGS or bone 
marrow failure. Further, silencing GUCY2C (Gucy2c-/- mice) did not alter the induction of 
apoptosis in small or large intestine in RIGS, in contrast to those earlier studies (see Fig. 4A). 
Moreover, silencing GUCY2C recapitulated the effects of eliminating p53 signaling (p53-/- mice), 
which also had no effect on apoptosis in small or large intestine in RIGS as reported previously 
(see Supplementary Fig. 8) (7). In the context of the role of GUCY2C in optimizing p53 injury 
responses, reinforced by the ability of Gucy2c-/- mice to phenocopy p53-/- mice (see 
Supplementary Fig. 2) (7), the primary mechanism amplifying epithelial disruption in RIGS in the 
absence of GUCY2C appears to be mitotic catastrophe, rather than apoptosis. 
Targeting p53 directly to prevent and treat RIGS has been uniquely challenging and treatments 
exploiting this mechanism have not yet emerged (7,9,12,14). The therapeutic challenge arises 
from the paradoxically opposite roles of p53 in RIGS and the radiation-induced hematopoietic 
syndrome, the two principal toxicities associated with radiation. Protection of epithelial cells by 
p53 has made its activation a target to treat RIGS (7-9,14,46). In striking contrast, radiation 
toxicity mediated by p53 in bone marrow has made its inhibition a target to treat the 
hematopoietic syndrome (8,46,55). Hence, p53 has remained an elusive target, requiring tissue-
specific strategies for appropriate directional regulation. The present study provides insights into 
novel molecular mechanisms underlying the pathophysiology of RIGS that can be readily 
translated into p53-targeted medical countermeasures to prevent and treat acute radiation-
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induced GI toxicity. Thus, GUCY2C has a narrow tissue distribution, selectively expressed by 
intestinal epithelial cells from the duodenum to the rectum (15-17). Further, GUCY2C is 
anatomically privileged, expressed in lumenal membranes of those cells, directly accessible to 
oral agents but inaccessible to the systemic compartment (17,31). Moreover, linaclotide 
(Linzess™) and plecanatide (Trulance™) are oral GUCY2C ligands recently approved for the 
treatment of chronic constipation syndromes, with negligible oral bioavailability or bioactivity 
outside the GI tract (31). The anatomical privilege of GUCY2C coupled with the 
compartmentalized activity of linaclotide and plecanatide, confined only to the intestinal lumen, 
offers a uniquely targeted approach to specifically engage p53-dependent mechanisms, 
compared to other available approaches, to prevent and treat RIGS. In turn, this offers 
prophylactic and therapeutic solutions to civilians, first-responders, and military personnel at risk 
from radiation disasters, like Chernobyl or Fukushima. Similarly, it provides a clinically-tractable 
approach for targeted prevention of GI toxicity from abdominopelvic radiotherapy for cancer, 
reducing dose-limiting toxicities and permitting greater radiation fractions to be administered, 
without altering the therapeutic radiosensitivity of extra-intestinal tumors (see Fig. 3I) (5). 
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FIGURE LEGENDS 
Figure 1. GUCY2C silencing amplifies RIGS. (A) Gucy2c-/- mice are more susceptible to death, 
compared to Gucy2c+/+ mice, induced by high dose (15 Gy) whole body irradiation (TBI, Kaplan-
Meier analysis, *** p<0.001; n=34 Gucy2c+/+ mice, n=39 Gucy2c-/- mice). (B) Mortality from low 
dose (8 Gy) TBI reflected hematopoietic toxicity, which was abrogated by bone marrow 
transplantation (BMT). In contrast, mortality from high dose TBI (15 Gy) reflected both 
hematopoietic and GI toxicity which could not be rescued by BMT [Kaplan-Meier analysis, *** 
p<0.001 between Gucy2c+/+ mice (n=11) and Gucy2c+/+ mice with BMT (n=5) following low dose 
(8 Gy) TBI; p<0.05 (not significant) between Gucy2c+/+ mice (n=21) and Gucy2c+/+ mice with BMT 
(n=15) following high dose TBI]. Following 18 Gy STBI, Gucy2c-/- mice were more susceptible to 
diarrhea (C, Chi-square test, two sided, * p<0.05), mortality (D, Kaplan-Meier analysis, ** p<0.01), 
weight loss (E, Frailty model analysis, * p<0.05), intestinal bleeding (F, fecal occult blood; FOB; 
Cochran-Mantel-Haenszel test, * p<0.05), debilitation (G, untidy fur; Cochran-Mantel-Haenszel 
test, * p<0.05), and stool water accumulation [H, Loess smoothing curves with 95% confidence 
bands and comparison of area under curve (AUC), * p<0.05; dashed line indicates stool water 
content before irradiation]. (I-L) Gucy2c-/- mice were more susceptible to radiation-induced GI 
injury in both small (I-J) and large (K-L) intestines quantified by crypt enumeration post irradiation 
(15 Gy TBI), compared to Gucy2c+/+ mice (ANOVA, * p<0.05, ** p<0.01, n>3 Gucy2c+/+ and  
Gucy2c-/- mice, respectively, at each time point). Bars in low power images represent 500 µm, 
and in high power images 50 µm, in I and K. n=34 Gucy2c+/+ mice, n=35 Gucy2c-/- mice in C-E and 
G; n=13 Gucy2c+/+ mice, n=13 Gucy2c-/- mice in F; n=26 Gucy2c+/+ mice and n=28 Gucy2c-/- mice 
in H. 
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Figure 2. The GUCY2C hormone axis is preserved in RIGS. (A-F) TBI (15 Gy) did not significantly 
alter the relative expression of (A) GUCY2C, (D) guanylin (GUCA2A), or (G) uroguanylin (GUCA2B) 
mRNA or (B) GUCY2C, (E) GUCA2A, or (H) GUCA2B protein in jejunum over time [n=4-8 per time 
point; p>0.05 (not significant) for mRNA or protein by ANOVA]. (C, F, I) Representative 
immunofluorescence images for the expression of GUCY2C, GUCA2A, and GUCA2B before and 48 
h after 15 Gy TBI [green, GUCY2C; red, hormone (GUA2A, GUCA2B); blue, DAPI]. Bar represents 
50 µm. 
Figure 3. Oral ST selectively opposes RIGS. (A-F) Gucy2c+/+ mice preconditioned with oral ST for 
14 d prior to and following 18 Gy STBI (on d 0), exhibited a lower incidence of diarrhea (A) induced 
by STBI, compared to mice treated with control peptide (CP) (Fisher’s exact test, two sided, * 
p<0.05). Similarly, following 18 Gy STBI, ST improved (B) diarrhea-free survival (Kaplan-Meier 
survival analysis, ** p<0.01); (C) weight loss and weight recovery (Frailty model analysis, * 
p<0.05); (D) FOB and (E) untidy fur (Cochran-Mantel-Haenszel test, * p<0.05); and (F) stool water 
content [Loess smoothing curves with 95% confidence bands and comparison of area under curve 
(AUC), *** p<0.001; dashed line, stool water content before irradiation]. (G-H) ST reduced 
radiation-induced intestinal damage 15 d following STBI, reflected by (G) gross morphology, with 
lower hyperemia, edema, and unformed stool, and (H) histology, without disruption of normal 
crypt-villus architecture quantified by crypt depth, stromal hypertrophy reflected by intestinal 
transmural thickness and lymphocytic infiltration (Fisher’s exact test, two sided, * p<0.05 in G; t-
test, two sided, *** p<0.001 in H; n=4 CP-treated mice, n=5 ST-treated mice). Bar in H represents 
100 µm. (I) Oral ST did not alter radiation responses by subcutaneous thymoma or melanoma (t 
test, two sided, p>0.05; dashed line, original tumor size). (J-K) Chronic (>2 weeks) oral ST did not 
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produce diarrhea (J) or growth retardation (K) (p>0.05, ANOVA). In A-F and I-K, n=9 CP-treated 
mice, n=9 ST-treated mice. 
Figure 4. GUCY2C signaling amplifies p53 response to RIGS by disrupting p53-Mdm2 interaction. 
(A) Silencing GUCY2C did not affect apoptosis induced by 15 Gy TBI in small intestine and colon 
(t-test, two sided, * p<0.05; Gucy2c-/- mice, n≥3 and Gucy2c+/+ mice, n≥3 at each time point). Oral 
ST improved (B) diarrhea-free survival [Kaplan-Meier analysis, ** p<0.01 between p53int+/+ mice 
treated with CP (n=17) or ST (n=16); p>0.05 between p53int-/- mice treated with CP (n=11) or ST 
(n=11)]; (C) weight [Frailty model analysis, * p<0.05 between p53int+/+ mice treated with CP (n=17) 
or ST (n=16); p>0.05 between p53int-/- mice treated with CP (n=11) or ST (n=11)]; and (D) FOB and 
(E) untidy fur [Cochran-Mantel-Haenszel test, * p<0.05 between p53int+/+ mice treated with CP 
(n=17) or ST (n=16); p>0.05 between p53int-/- mice treated with CP (n=11) or ST (n=11)] following 
18 Gy STBI in p53int+/+, but not p53int-/-, mice. (F) Oral ST promoted p53 phosphorylation in small 
intestine 7 d after 18 Gy STBI (t-test, two sided, * p<0.05, n=6 in CP and n=6 in ST treated mice). 
Bar represents 50 µm. (G) 8-Br-cGMP increased total and phosphorylated p53 in response to 5 
Gy radiation in HCT116 human colon carcinoma cells (n≥3 in each treatment group; * p<0.05, ** 
p<0.01, ANOVA). (H) 8-Br-cGMP increased p53 activation in HCT116 cells in response to 5 Gy 
radiation by disrupting p53-Mdm2 interaction, quantified by immunoprecipitation (IP) and 
Western Blot (WB) with antibodies to p53 or Mdm2 (n≥3 in each group; * p<0.05, ** p<0.01, 
ANOVA). Mouse and rabbit IgG was used as isotype controls in (H). 
Figure 5. GUCY2C signaling requires p53 to oppose mitotic catastrophe. (A) Oral ST reduced DNA 
double strand breaks (γ-H2AX; t-tests, two sided, *** p <0.001, n=4 mice treated with CP treated, 
n=5 mice treated with ST; >200 crypts were examined in each mouse) and (B) abnormal mitotic 
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orientation [(%) of metaphase plates oriented non-orthogonally to the crypt-surface axis)] (t-
tests, two sided, * p<0.05; n=4 mice treated with CP treated, n=5 mice treated with ST; >50 
mitotic figures were evaluated in each mouse intestine) following 18 Gy STBI (red, β-catenin; 
green, γ-H2AX; blue, DAPI). Bars represent 50 µm. (C) Radiation (5 Gy)-induced anaphase bridging, 
a marker of abnormal mitosis quantified by the anaphase bridge index (ABI), in wild type 
(parental) and p53-null (p53-/-) HCT116 human colon carcinoma cells, was reduced by 
pretreatment with a cell-permeant analogue of cGMP in a p53-dependent fashion. 
Representative images of ABI: i, normal mitosis without anaphase bridge, ii-iii, abnormal mitoses 
with anaphase bridges (Chi-square tests, two sided, * p<0.05; >100 cells in anaphase were 
examined in each group). (D) Radiation (5 Gy)-induced aneuploidy, quantified by centrosome 
enumeration, in parental and p53-null HCT116 cells, was reduced in a p53-dependent fashion by 
pretreatment with 8-Br-cGMP. Representative images of ploidy: i, normal diploidy, ii, abnormal 
diploidy, iii, triploidy, iv, tetraploidy. (red, α/β-tubulin; green, γ-tubulin; purple, DAPI) (Chi-square 
tests, two sided, *** p<0.001, >200 mitotic cells were examined in each group). (E) Cytogenetic 
toxicity induced by increasing doses of radiation, quantified by colony formation, in parental and 
p53-null HCT116 cells was reduced in a p53-dependent fashion by pretreatment with 8-Br-cGMP 
[Pairwise comparison of isotherm slopes, * p<0.05: HCT116 cells treated with cGMP compared 
to the three other groups including HCT116 cells treated with PBS, HCT116 p53-null cells treated 
with PBS or cGMP; p>0.05 (not significant) between any two of these three latter groups]. 
